Alan Raffauf, M.A. Appointed Widex Vice President of Marketing

Reaffirming its commitment to serve as the ally of the independent audiologist, Widex Inc. today announced the appointment of industry veteran Alan Raffauf, M.A. to the position of Vice President of Marketing, reporting directly to Sheena Oliver, Chief Marketing Officer, U.S.

“Alan is both an experienced B2B and B2C marketer and a professional audiologist,” Oliver said today. “As such, he brings to Widex a strong understanding of and appreciation for what today’s independent audiologists need to grow and expand their practices. Informed by his professional experience and educational background, Alan will lead the development of all Widex marketing programs, working closely with an already-stellar team of branding, creative, digital, and communications professionals.”

Alan Raffauf comes to Widex from Oticon Medical, where since 2009 he served as Vice President of Marketing with responsibility for the go-to-market readiness and lifecycle management of bone-anchored hearing products and cochlear implants for the United States and Canada. As such, he led all B2B and B2C marketing, the online patient community and advocate program, the insurance support services program, all daily operations, as well as the enterprise resource planning system.

Commenting on his appointment, Raffauf emphasized that he was joining a winning team that was growing the business. “Widex has many of the strategic pieces in place to grow at a rate that outpaces the industry,” he said today. “I am excited to join a team that is so totally committed to the independent channel. I view marketing from the perspective of the hearing care professional. I see the world through their eyes. I know what their needs are, and I am committed to developing the programs that exceed these needs.”

Prior to this position, from 2003 to 2009, he served as an Oticon Product Manager in the United States and Denmark. Finally, as a Government Services Coordinator and Staff Audiologist, he managed the VA/DDC hearing aid contract, as well as marketing and training responsibilities.

Alan Raffauf holds a Master’s Degree, Audiology/Audiologist from The College of New Jersey and a Bachelor of Arts degree in Communication Sciences and Disorders from the University of Connecticut.

SourceWIDEX

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version